Sentence examples for marker for reduced from inspiring English sources

As a result of this clinical data, NCCLS currently recommends testing of extra-intestinal Salmonella isolates for nalidixic acid resistance as a marker for reduced fluoroquinolone susceptibility [ 4].

However, serum creatinine, which is one of the main AKI biomarkers used in clinical settings, is a late marker for reduced glomerular filtration rate, which limits its use in early AKI detection and clinical therapeutic studies [ 3].

Among the IDC cases, Cox multivariate regression analysis showed nuclear Ep-ICD to be the most important prognostic marker for reduced disease-free survival (p = 0.011, HR = 80.18, 95% C.I. = 2.73 2352.2).

However, as mentioned earlier, IDeg has been shown to have a beneficial effect on hypoglycaemia compared to IGlar 4. Hypoglycaemic events, both non-severe and severe, are known to be a key marker for reduced HRQoL in diabetes 1.

In particular, cutaneous SCC is known to be associated with immunosuppression [ 6, 8, 9], but whether it is a reliable marker for reduced immune competence that could explain these findings is unknown.

In addition to the identified candidate nsSNPs for increased or reduced arsenic responsiveness, we observed i) a nsSNP that results in the breakage of a disulfide bond, as candidate marker for reduced arsenic responsiveness of KLK7, a secreted serine protease participate in normal shedding of the skin; and ii) 6 pairs of vicinal cysteines in KLK7 protein that could be binding sites for arsenic.

The genetic profiles identified should be further examined to clarify their potential as molecular markers for reduced boar taint.

29 33 Especially the AV-plane velocities 25 34 and two-segment systolic longitudinal strain and strain rate 33 have proven to be more sensitive than fractional shortening as markers for reduced myocardial performance after perinatal asphyxia.

The presence of islet autoantibodies in cord blood may also be a marker of reduced risk for T1D in offspring [ 41, 42].

23 If only more aggressive prostate cancer diagnoses are markers of reduced risk for subsequent cancers, then the difference between rates of new primary cancer in prostate cancer patients and men free of this disease in the US population would be diluted given the case mix.

This implies an adequate sensitivity of the two-marker blood test for reducing CRC mortality if used as a screening test but this prediction requires validation in true screening populations.